Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

OS Therapies Inc

OSTX ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.55

▼ -2.52%

Market Cap $72.03M · Vol 45.41K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$72.03M

Micro Cap

Div Yield

N/A

EPS Growth

+26.53%

YoY

RSI (14)

42.86

Momentum

Beta

N/A

vs Market

52W High

$2.52

38.49% below

52W Low

$1.16

34.20% above

Volume

45.41K

Avg 31.59K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

78.79%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, OS Therapies Inc (OSTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OSTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.44%

+1.97%

-10.40%

+19.23%

YTD

+10.71%

-37.50%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-28,753,840.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-464.58% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+26.53%
Outstanding Shares	46.47M

Technical Indicators

50-Day SMA	$1.64
200-Day SMA	$1.59
RSI (14)	42.86
Beta	N/A
52-Week High	$2.52
52-Week Low	$1.16

Volume Today	45.41K
Avg Daily Volume (30D)	31.59K
Relative Volume	1.44x
Volatility (10D)	65.78
Volatility (30D)	53.70
Free Float	78.79%

Analyst Consensus

BUY

Current Price $1.55

Mean Target $8.50

52W Low$1.16 52W High$2.52

Current

Target

$1.16 $2.52

Current Analyst target

+448.39% upside potential · 5 analysts

Identifiers

ExchangeNYSE American

FIGIBBG00Y71N7H6

ISINUS68764Y2072

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 16, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -3.94% ARGX.BR argenx SE -4.19% ARGX argenx SE -2.76% INSM Insmed Inc -1.42% 2269.HK WuXi Biologics (Cayman) Inc -4.71%

Company Profile

OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.